Cancer clot care: do longer blood thinners help or harm?

NCT ID NCT07388056

Completed Knowledge-focused Sponsor: Thammasat University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study reviewed medical records of 169 cancer patients who had blood clots and took blood thinners for at least six months. Researchers compared extended use of lower-dose blood thinners versus standard doses to see which better prevents new clots and reduces bleeding. The goal is to find the safest, most effective long-term treatment for cancer-associated thrombosis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Anticoagulants (blood thinners such as warfarin, low molecular weight heparin, and DOACs)

What this could lead to

If successful, this could help doctors decide the best duration and dose of blood thinners for cancer patients with blood clots, potentially reducing clot recurrence and bleeding risks.

What could go wrong

This is a retrospective observational study, not a controlled trial, so results may show associations but not prove cause and effect. The small sample size and single-center design limit how widely the findings can be applied.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER-ASSOCIATED THROMBOSIS